Introduction
'If a fright or despondency lasts for a long time, it is a melancholic affection'
Hippocrates, Aphorisms, Section 6, no. 23
Depression has been recognized as a distinct and serious condition for more than 2000 years. Although definitions have varied, the core construct of depression has remained intact: a condition of despondency and anergia akin to normal sadness, but crucially different in its severity, duration and/or lack of a triggering event. In modern psychiatry, major depressive disorder (MDD; Glossary) is broadly defined as a syndrome including episodes of persistent negative mood (feeling down, sad, blue, etc.) or anhedonia (a loss of interest in pleasurable activities), plus a combination of additional emotional, psychological and somatic symptoms (Box 1) [1] . This constellation of symptoms must persist for at least two weeks and not be secondary to an obvious substance, medical condition, or other psychiatric disorder; neither can the symptoms be better explained by normal grief. This definition emerged from efforts to develop reliable diagnostic criteria for use in clinical and research settings, culminating in the Diagnostic and Statistical Manual of the American Psychiatric Association [currently in its 4th edition (DSM-IV-TR)] [1].
Here, we describe the inadequacy of available antidepressant treatments and conclude that a shift is needed in the definition of depression and the research agenda going forward. We provide a brief overview of the epidemiology of depression, including the high prevalence of treatmentresistant depression (TRD). We then present a brief history of antidepressant treatment development and emphasize that, after several decades of research, antidepressant efficacy has not substantially improved. We next consider the most commonly posited explanation for this, namely the clinical heterogeneity of the disorder, which suggests different biological subtypes of depression. We conclude that the current construct of depression, as defined for the purposes of clinical and basic research, has lost its utility. We note that focusing investigation towards specific symptoms considered core to the illness might be more fruitful in elucidating the neurobiology of the disease and developing improved treatments. Moreover, we propose that the illness 'depression' is better defined as the inability to disengage from a negative mood state and the tendency to re-enter this state inappropriately: that is, the tendency to get 'stuck in a rut'. These propositions are supported by emerging data on deep brain stimulation (DBS) in the treatment and study of depression.
The extent and cost of depression
The US lifetime prevalence of MDD is 17%, with twice as many women affected as men [2] . Median age of symptom onset is 30 years, although the disorder can arise at almost any age [2] . MDD is moderately heritable (ranging from 30% to 40%) [3] , supporting a role for both genetic and environmental risk factors. MDD is the leading cause of years lost owing to disability worldwide and the third overall contributor to the worldwide burden of disease (but projected to be the biggest contributor by 2030) [4] .
Several treatments are available for depression, including medications, psychotherapy and various somatic treatments, such as electroconvulsive therapy (ECT), vagus nerve stimulation (VNS) and transcranial magnetic stimulation (TMS). Unfortunately, up to two-thirds of patients remain symptomatic following first-line treatment [5] and a third fail to achieve remission (defined as full resolution of depressive symptoms) after four established treatments [6] ; approximately 10-20% of depressed patients can show little if any improvement despite multiple, often aggressive treatments. Thus, a conservative estimate places the US prevalence of TRD at 1-3%. Importantly, this estimate does not include the prevalence of dysthymia or treatment-resistant bipolar depression.
Even among those patients who achieve remission with antidepressant treatment, recurrence is the rule rather than the exception: the probability of another depressive episode is >60% after the first, >70% after the second, and 
